Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.30 |
| ▸ | ACR | P10323 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728970 | 0.82 | CYP1A2 (0.38) | S1PR1S1PR3 | |
| SCHEMBL17858732 | 0.78 | CYP2A6 (0.42) | S1PR1S1PR3 | |
| SCHEMBL19728990 | 0.77 | KIF11 (0.47) | PTPN1KIF11 | |
| SCHEMBL19737072 | 0.74 | LMNA (0.35) | PTPN1GABRA1GABRB2 | |
| SCHEMBL24250988 | 0.72 | RAB9A (0.48) | S1PR1S1PR3KIF11 | |
| SCHEMBL29750736 | 0.71 | XDH (0.38) | XDHGABRA1GABRB2KIF11 | |
| SCHEMBL12459123 | 0.69 | CHRNB1 (0.41) | GABRA1KIF11 | |
| SCHEMBL8378894 | 0.68 | CYP2A6 (0.48) | — | |
| SCHEMBL19736896 | 0.68 | KMT2A (0.41) | GABRA1GABRB2KIF11 | |
| SCHEMBL12458881 | 0.67 | CYP19A1 (0.38) | XDHKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-01-28 | — | — | US | disclosed |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023085-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | S1PR1 4540/4885S1PR3 3960/4885XDH 4160/4885 |
| US-10842791-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | S1PR1 4540/4885S1PR3 3960/4885XDH 4160/4885 |
| US-20190167686-A1 | SMALL MOLECULE INHIBITORS OF EGFR AND PI3K | EGFR, ERBB2, ERBB3 | S1PR1 4540/4885S1PR3 3960/4885XDH 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.